<DOC>
	<DOCNO>NCT01310868</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , Gliadel wafer temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving radiation therapy temozolomide surgery Gliadel wafer may kill tumor cell remain surgery . PURPOSE : This phase II trial study side effect fluorescence-guided surgery 5-ALA give together Gliadel wafer , follow radiation therapy temozolomide , treat patient primary glioblastoma .</brief_summary>
	<brief_title>Gliadel Wafer Fluorescence-Guided Surgery With 5-ALA Followed Radiation Therapy And Temozolomide Treating Patients With Primary Glioblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish combine use 5-ALA Gliadel wafer fluorescence-guided radical brain tumor resection safe compromise patient primary glioblastoma receive complete adjuvant standard radiotherapy plus temozolomide . Secondary - To gather preliminary evidence combine use 5-ALA Gliadel wafer surgery potential improve clinical outcome , via measurement time clinical progression . - To gather preliminary evidence regimen surgery potential improve clinical outcome via measurement survival 24 month . OUTLINE : This multicenter study . Gliadel wafer apply resection cavity immediately 5-ALA fluorescence-guided radical brain tumor resection . After recovery surgery ( within 6 week surgery possible ) , patient receive adjuvant chemoradiotherapy comprise standard radiotherapy temozolomide . Tumor biopsy blood sample may collect time surgery retrospective MGMT status analysis . After surgery , patient follow post-surgical visit , subsequent therapy routine clinic visit , 12 , 18 , 24 month . Peer review funded Cancer Research UK .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<mesh_term>Levulinic acid</mesh_term>
	<criteria>INCLUSION CRITERIA . The patient review specialist neurooncology multidisciplinary team ( MDT ) . ii . Stealth MRI ( neuronavigation ) perform prior surgery . iii . Imaging evaluate neuroradiologist judged typical appearance primary GBM iv . Radical resection judge realistic neurosurgeon MDT ( i.e . NICE criterion use Carmustine wafer meet ) v. WHO performance status 0 1 vi . Age ≥18 vii . Patient judge MDT fit standard radical aggressive therapy GBM ( resection follow RT concomitant adjuvant temozolomide ) EXCLUSION CRITERIA i. GBM think transform low grade secondary disease ii . The patient see specialist MDT . iii . There uncertainty radiological diagnosis iv . 5ALA Carmustine wafer contraindicate ( inc know suspected allergy 5ALA porphyrin , acute chronic type porphyria ) v. Pregnant lactate woman vi . Known suspect HIV significant infection comorbidity would preclude radical aggressive therapy GBM vii . Active liver disease ( ALT AST ≥5 x ULRR ) viii . Concomitant anticancer therapy except steroid ix . History malignancy ( except adequately treat basal squamous cell carcinoma carcinoma situ ) within 5 year x . Previous brain surgery ( include biopsy ) cranial radiotherapy xi . Platelets &lt; 100 x109/L xii . Mini mental status score &lt; 15</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>